文献速递白血病淋巴瘤造血干细胞移植与细胞治疗

在免疫健全模型中改善慢性淋巴细胞白血病T细胞线粒体功能障碍以增强CAR-T细胞疗法

Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model.
PubMed 文献 · Blood Adv · 2025-01-01

本研究探讨慢性淋巴细胞白血病(CLL)患者T细胞线粒体功能障碍及其对自体CAR-T细胞疗法的影响。整合代谢与功能分析显示,未经治疗CLL患者所有T细胞亚群均存在线粒体受损和去极化,多组学分析揭示线粒体信号改变、AMPK和自噬活性降低、糖酵解上调伴Akt过度活化。在CLL T细胞培养中抑制PI3K/Akt通路可诱导代谢重编程,增强线粒体活性和记忆分化;在免疫健全小鼠模型中,CAR-T细胞制备过程中添加PI3Kδ抑制剂idelalisib可改善持久性和长期无白血病缓解。

要点

  • 未经治疗CLL患者所有T细胞亚群均存在线粒体受损和去极化。
  • CLL T细胞显示AMPK和自噬活性降低、糖酵解上调伴Akt过度活化。
  • 培养中抑制PI3K/Akt可增强线粒体活性和记忆分化。

核心结论

  • 调节异常的CLL T细胞代谢可能增强自体T细胞疗法的疗效。

研究设计与样本

  • 整合代谢与功能分析、离体和体内小鼠研究,以及转录组和表观基因组多组学分析。
  • 在免疫健全小鼠模型中进行CAR-T细胞制造和功能评估。

主要发现

  • 未经治疗CLL患者所有T细胞亚群均存在线粒体受损和去极化。
  • 多组学分析显示线粒体信号显著改变、AMPK和自噬活性降低、糖酵解上调伴Akt过度活化。
  • CLL T细胞培养中抑制PI3K/Akt通路诱导代谢重编程,增强线粒体活性、PGC-1α表达和记忆分化。
  • 免疫健全小鼠模型中,CAR-T细胞制造过程中添加PI3Kδ抑制剂idelalisib改善持久性和长期无白血病缓解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An unmet clinical need in chronic lymphocytic leukemia (CLL) is emerging due to the rapidly expanding group of patients with double refractory (Bruton's tyrosine kinase- and B-cell lymphoma 2-inhibitor) disease. So far, autologous T-cell-based therapies, including chimeric antigen receptor (CAR) T cells, have limited success in CLL, which has been attributed to an acquired CLL-mediated T-cell dysfunction and subset skewing toward effector cells at the expense of memory formation. T-cell responses rely on dynamic metabolic processes, particularly mitochondrial fitness. Although mitochondrial disruptions have been observed in solid tumor-infiltrating lymphocytes, their impact on T-cell immunity in lymphoproliferative disorders is unknown. Recent findings indicate that mitochondrial mass in CAR T cells correlates with CLL clinical outcomes. This prompted our investigation into the mitochondrial fitness in CLL T cells. Integrated metabolic and functional analyses revealed impaired, depolarized mitochondria across all T-cell subsets in untreated patients with CLL, leading to further ex vivo and in vivo mouse studies on the underlying signaling alterations. Multiomics profiling of transcriptome and epigenome revealed significant alterations in mitochondrial signaling, diminished adenosine monophosphate-activated protein kinase and autophagy activity, and upregulated glycolysis coupled with hyperactivation of Akt. Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway during CLL T-cell culture induced metabolic reprogramming, enhancing mitochondrial activity, expression of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha, and memory differentiation. Underscoring clinical relevance, supplementation with the PI3Kδ inhibitor idelalisib during CAR T-cell manufacturing improved persistence and long-term leukemia-free remissions in an immunocompetent murine model. Our study suggests that modulating the abnormal CLL T-cell metabolism can enhance the efficacy of autologous T-cell therapies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gamal W, Goedhart NB, Simon-Molas H, et al. Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model. Blood Adv. 2025. PMID: 39938006. doi:10.1182/bloodadvances.2024014822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。